Market research
RETA Reata Pharmaceuticals Inc
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 7B
- P/E ratio
- Not available
- Analyst target
- 172.4
- Dividend yield
- 0.0%
- Beta
- 1.42
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US75615P1030
- Market cap
- 7B
- P/E ratio
- Not available
- Analyst target
- 172.4
- Dividend yield
- 0.0%
- Beta
- 1.42
About
About Reata Pharmaceuticals Inc
Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases. The company is developing Phase 3 clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney disease (CKD) caused by Alport syndrome, as well as for a form of pulmonary arterial hypertension associated with connective tissue disease; omaveloxolone to treat Friedreich's ataxia; and conduct various form of CKD, such as, type 1 and type 2 diabetic CKD, type 1 and type 2 diabetic CKD, hypertensive CKD, focal segmental glomerulosclerosis, and others. It is also developing RTA 901 for neurological diseases; and bardoxolone for the treatment of autosomal dominant polycystic kidney disease. In addition, the company has a strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize bardoxolone for renal, cardiovascular, diabetes, and various other related metabolic indications in Japan, China, Hong Kong, Macao, South Korea, Taiwan, Thailand, Singapore, the Philippines, Malaysia, Indonesia, Brunei, Vietnam, Laos, Myanmar, and Cambodia; AbbVie Inc. to jointly research, develop, and commercialize all second- and later-generation Nrf2 activators for all indications other than renal, cardiovascular, and metabolic indications. Reata Pharmaceuticals, Inc. was incorporated in 2002 and is headquartered in Plano, Texas. As of September 26, 2023, Reata Pharmaceuticals, Inc. operates as a subsidiary of Biogen Inc.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the RETA discussion.
5 years, 4 months ago
Reata Pharmaceuticals, Inc is currently in a long term uptrend where the price is trading 14.9% above its 200 day moving average.
From a valuation standpoint, the stock is 72.3% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 371.4.
Reata Pharmaceuticals, Inc's total revenue rose by 19.5% to $3M since the same quarter in the previous year.
Its net income has increased by 64.8% to $-66M since the same quarter in the previous year.
Finally, its free cash flow grew by 69.6% to $-46M since the same quarter in the previous year.
Based on the above factors, Reata Pharmaceuticals, Inc gets an overall score of 5/5.